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Summary Angioscopy enables macroscopic pathological diagnosis of cardiovascular diseases
from the inside. This imaging modality has been intensively directed to characterizing vul-
nerable coronary plaques. Scoring of plaque color was developed, and based on prospective
studies; dark yellow or glistening yellow plaques were proposed as vulnerable ones. Colorime-
try apparatus was developed to assess the yellow color of the plaques quantitatively. The
effects of lipid-lowering therapies on coronary plaques were conﬁrmed by angioscopy. However,
since observation is limited to surface color and morphology, pitfalls of this imaging technol-
ogy became evident. Dye-staining angioscopy and near-infrared ﬂuorescence angioscopy were
developed for molecular imaging, and the latter method was successfully applied to patients.
Color ﬂuorescence angioscopy was also established for molecular and chemical basis charac-
terization of vulnerable coronary plaques in both in vitro and in vivo. Drug-eluting stents (DES)
reduce coronary restenosis signiﬁcantly, however, late stent thrombosis (LST) occurs, which
requires long-term antiplatelet therapy. Angioscopic grading of neointimal coverage of coro-
nary stent struts was established, and it was revealed that neointimal formation is incomplete
and prevalence of LST is higher in DES when compared to bare-metal stent. Many new stents
were devised and they are now under experimental or clinical investigations to overcome the
shortcomings of the stents that have been employed clinically. Endothelial cells are highly anti-
thrombotic. Neoendothelial cell damage is considered to be caused by friction between the cells
and stent struts due to the thin neointima between them that might act as a cushion. Therefore,
development of a DES that causes an appropriate thickness (around 100m) of the neointima is
a potential option with which to prevent neoendothelial cell damage and consequent LST while
preventing restenosis.
© 2011 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Angioscopy enables macroscopic pathological diagnosis of
cardiovascular diseases from the inside. This imaging
modality has been intensively directed to characterizing
vulnerable coronary plaques. Scoring of plaque color was
developed, and based on prospective studies, dark yellow or
glistening yellow plaques were proposed as vulnerable ones.
Colorimetry apparatus was developed to assess the yellow
color of the plaques quantitatively.
The effects of lipid-lowering therapies on coronary
plaques were conﬁrmed by angioscopy. However, since
observation is limited to surface color and morphology, pit-
falls of this imaging technology became evident.
Dye-staining angioscopy and near-infrared ﬂuorescence
angioscopy were developed for molecular imaging, and the
latter method was successfully applied to patients. Color
ﬂuorescence angioscopy was also established for molecular
and chemical basis characterization of vulnerable coronary
plaques in both in vitro and in vivo.
Drug-eluting stents (DES) reduce coronary restenosis sig-
niﬁcantly, however, late stent thrombosis (LST) occurs,
which requires long-term antiplatelet therapy. Mechanisms
of LST were clariﬁed considerably by angioscopy.
This article describes the past and present status of coro-
nary angioscopy.
n
r
d
uevelopmental history of coronary angioscopy
n August 31, 1945, a big storm hit the Kanto district of
apan. Trains were stopped for several hours due to the
torm and Tsutomu Uji, a surgeon from Tokyo University and
asanao Sugiura of Olympus Company happened to meet
n the train. A concept of new endoscope was discussed,
hich could be the start of the development of endoscopy
n Japan.
In December 1949, in collaboration with Masao Fukaomi
nd Minoru Maruyama, they developed a ﬂexible gastroscope
2mm in diameter with ﬁlms and illumination source in the
istal most tip. Anesthetized dogs were successfully exam-
ned with this endoscope.
Takeshi Sakamoto used this endoscope for the ﬁrst time
s a gastroscope. A ﬂexible gastroscope thus developed
as provided the basic structure for bronchoscopes, cysto-
copes, etc.
Several years later, this gastroscope was replaced by a
berscope which was more ﬂexible and more easy to be
anipulated. Fiberscopes have been widely applied to diag-
osis and treatment not only of digestive tracts but also
espiratory and urogenital tracts as an essential tool.
Although an endoscope was clinically applied to the heart
uring surgery by Allen in 1922 [1], many years elapsed
ntil percutaneous transluminal coronary angioscopy was
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Figure 1 Angioscopic images of a coronary plaque before and after disruption. A 60-year-old male. A glistening yellow plaque in
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the proximal segment of the right coronary artery before (blac
) and thrombus formation (white arrow in B) observed 3-h afte
eproduced from Uchida et al. [15], with permission.
erformed. This was due to the difﬁculty in the displace-
ent of blood in the artery and the need for more ﬂexible
nd thinner endoscope.
With anticipation for clinical application, we (the author
nd employees of Olympus Co) began to develop a new ﬁber-
cope for coronary use in 1976 Thrombosis and thrombolysis
n the removed human coronary artery and the changes
nduced by balloon angioplasty were successfully observed
y this endoscope in 1986 [2].
Meanwhile, Spears observed coronary ostia by the use
f a broncoscope [3]. Also, coronary arterial changes were
bserved mainly intraoperatively by Litvack [4].
Using ﬁberscopes specially designed for coronary use,
he author observed percutaneously from proximal to distal
oronary segments in patients with ischemic heart dis-
ase (1984, 1987) [5]. Observation of plaque disruption
nd thrombi in acute coronary syndromes (ACS) was per-
ormed by Hoeler [6]. Evaluation of coronary interventions
y POBA was performed by the author (1989) [7,8]. Coronary
ntervention by laser was evaluated by the author (1987),
akamura [9], and evaluation of coronary interventions by
tent by Ueda [10]. Stent and cutting balloon were studied
y many investigators. Application of percutaneous coronary
ngioscopy was extended to diagnosis of Kawasaki disease by
shikawa [11].
Thus, percutaneous angioscopy is now routinely per-
ormed for examinations of underlying mechanisms
f ACS [12], for selection of therapeutic modali-
ies, for evaluation of medical [13], interventional
14], and surgical therapies and for prediction of ACS
15].
ulnerable coronary plaques
t is still not predictable, in whom, when, where and during
hat she (he) is doing, ACS occur. If they become pre-
ictable, it is a great gospel for mankind. Many workers have
evoted time to characterize vulnerable coronary plaques
hat trigger these fatal syndromes. However, characteriza-
ion of vulnerable coronary plaques is still not established.
Q
A
low in A) and disruption of the identical plaque (black arrow in
onset of acute coronary syndrome.
Vulnerabilty has two aspects of meaning; one is the frag-
le plaques that are easily disrupted by mechanical stimuli
nd another is the plaques rapidly progressing toward frag-
le ones by inﬂammatory or metabolic processes. In clinical
ituations, the former are usually considered as vulnerable
nes.
etection of vulnerable coronary plaques by
ngioscopy
ngioscopy has contributed to understanding the underlying
echanisms of ACS.
It was found that thrombus formation on the disrupted
ellow coronary plaques is the typical causative mechanism
f ACS in the majority of patients [4]. Therefore, a certain
roup of yellow plaques has been considered as vulnerable
o disruption.
Fig. 1 demonstrates angioscopic images of a yellow
laque before and immediately after the onset of ACS (ST-
levation myocardial infarction). Disruption of the identical
laque and thrombus formation on it were evident after the
nset of attack [15].
lassiﬁcation of plaque color
coring of vulnerability by surface color was made; namely
hite, light yellow, yellow, and dark yellow as 0, 1, 2, and
respectively; or white, light yellow, yellow, and glisten-
ng yellow plaques as 0, 1, 2, and 3, respectively [16—18]
Fig. 2).
Since dark yellow and glistening yellow plaques often
ave thin ﬁbrous cap with lipid pool beneath by histology,
ntravascular ultrasonography (IVUS) or optical coherence
omography (OCT), they are proposed as vulnerable ones.uantitative analysis of plaque color
ngioscopic color assessment of plaques is inﬂuenced by
ight irradiated onto them. Furthermore, yellow color
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yellow plaques, respectively.
grading is often different from observer to observer. There-
fore, intra- and interobserver observation system has been
employed for color grading.
In order to avoid this rather subjective grading, a quan-
titative color analysis was attempted. Ishibashi et al. and
Okada et al. developed a colorimetry apparatus for quanti-
tative assessment of yellow color of the plaques, and they
found that the plaques with high yellow color are vulnerable
to thrombosis [19,20].
Angioscopic identiﬁcation of vulnerable plaques by
surface color
Although scoring of vulnerabilty by depth of yellow color
is one approach for characterization of vulnerable plaques,
relationships between depth of yellow color and histologi-
cal vulnerability remain unclear. It was reported that yellow
color of human coronary plaques is determined by deposition
of -carotene, and in addition to its concentration, its depo-
sition with cholesteryl esters increases depth of yellow color
[21]. Therefore, relationships between histological changes
and molecular imaging of lipids should be examined for more
speciﬁc diagnosis of vulnerable coronary plaques.
Since angioscopic observation is limited to surface color
and morphology, the histological and molecular changes
inside the plaque are beyond the scope of this imaging tech-
nology.
Prediction of acute coronary syndromes by
angioscopy
It was reported that the glistening yellow plaques are prone
to disrupt and ACS more frequently develop in patients hav-
ing this type of plaque and the changes in the identical
c
t
m
ito E: white, light yellow, yellow, dark yellow, and glistening
laques before and immediately after onset of ACS were
bserved by angioscopy. It was revealed that ACS developed
n 3.3% of white plaque group, 7.6% of non-glistening yellow
laque group, and 68.4% of glistening yellow plaque group
15].
Ohtani et al. followed up 552 patients by angioscopy for
7.3 months. ACS events occurred in 7.1%. Patients with
umber of yellow plaques ≥2 and ≥5 had 2.2 and 3.8-fold
igher event rates, respectively than those with number of
ellow plaques 0 or 1 [22].
elations of angioscopic images to those by
ntravascular ultrasonography (IVUS), optical
oherence tomography (OCT) and computed
omography (CT)
oronary plaques were analyzed by angioscopy and OCT in
ombination by Takano et al. They observed an inverse rela-
ion between color grade and ﬁbrous cap thickness [23].
omatsu et al. classiﬁed coronary plaques by multi-detector
ow computed tomography into soft, intermediate, and cal-
iﬁed plaques, and he found good correlation between soft
laque and angioscopic yellow plaque [24].
itfalls of angioscopy in detecting vulnerable
laques
he yellow color of the plaques is mainly caused by -
arotene which coexists with lipids in the vascular wall, and
herefore it is an indirect marker of vulnerability.
All prospective studies indicate that yellow plaques are
ore prone to disruption than white plaques, but do not
ndicate that all yellow plaques become disrupted.
22
Table 1 Histological classiﬁcation of coronary plaques
based on distribution of lipids, calcium, collagen ﬁbers, and
macrophage-foam cells.
Angioscopy Histology
Superﬁcial lipid deposition
group
CF-dense subtype
CF-loose subtype
CF-scanty subtype
Glistening yellow plaques Diffuse lipid deposition group
Non-NC type
CF-dense subtype
CF-loose subtype
CF-scanty subtype
NC type
Non-glistening yellow
plaques
Non-calciﬁed cap type
CF-dense, CF-loose,
CF-scanty subtypes
Calciﬁed cap type
CF-dense, CF-loose,
CF-scanty subtypes
White plaques Non-lipid deposition group
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The limited incidence of ACS in patients having yellow
laques (even in high yellow plaque patients and multi-
le yellow plaque patients) suggests the existence of both
table and vulnerable plaques in the yellow plaque group.
CS developed, although at a lower incidence (4%), in
atients in whom white plaques but not yellow plaques were
etected. Furthermore, disrupted white coronary plaques
ere observed in a prospective study [15]. This ﬁnding sug-
ests the existence of vulnerable white plaques.
Coronary arteries are muscular arteries, and therefore
oronary arteries and the plaques therein are protected
gainst disruption by normal collagen ﬁbers (CFs). During
laque growth, CFs degenerate, are disrupted, and ﬁnally
estroyed.
Occlusive thrombosis occurs on the damaged (irrespec-
ive of erosion, ulcer, or lipid pool disruption) superﬁcial
ayers of the coronary plaques, and results in ACS. There-
ore, demonstrating the lack of normal CFs together with
ipids and macrophages in the superﬁcial layers of the
laques is an essential requisite for the detection of vul-
erable plaques. However, detailed examinations of the
elationships between angioscopic color images and the dis-
ribution of CFs are currently lacking.
In our study, white and yellow plaques were histologi-
ally classiﬁed into three and seven subtypes, respectively
Table 1). CF-loose-to-scanty subtype of superﬁcial lipid
eposition group, CF-loose-to-scanty cap subtype of lipid
ool (necrotic core) type, and calciﬁed cap subtype of lipid
ool type in diffuse lipid deposition group of yellow plaques
ere considered to be vulnerable. These subtypes exhibited
listening yellow color, suggesting this color is a marker of
ulnerable plaques [25,26].
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vulnerable coronary plaque has a thin ﬁbrous cap
ith a large lipid core beneath: A fact or story?
plaque having a thin ﬁbroatheromatous cap with a large
ipid core beneath has been believed to be vulnerable. Based
n this hypothesis, intensive clinical studies have been car-
ied out to investigate this type of plaque using IVUS and
CT. However, ACS do not necessarily develop in patients
aving a thin capped lipid core. Therefore, the thickness
f the cap was measured in a pathohistological study. How-
ver, there were no signiﬁcant differences in cap thickness
mong the CF-dense (histologically stable), CF-loose-to-
canty (histologically vulnerable), and calciﬁed cap subtypes
histologically vulnerable), indicating that cap thickness did
ot necessarily represent vulnerability [25].
Whether the hypothesis ‘‘the vulnerable plaque has a
hin ﬁbrous cap with a large lipid core beneath’’ is a fact
r story should be settled.
re-stage of erosion
laque erosion is observed in around 25% of patients with
CS, and sudden death not infrequently occurs in this group
f patients [27,28]. Although erosion can be detected by
ngioscopy and OCT, what kind of images represents the pre-
tage of erosion by these and other imaging tools had been
nclear. We conceived that jelly-like type in white plaque,
F-scanty subtype of superﬁcial lipid deposition group, and
alciﬁed cap subtype of yellow plaques were a pre-stage of
rosion.
cute coronary syndromes without obvious
oronary plaque disruption
here are patients with ACS in whom disrupted coronary
laques are not detectable. Persistent coronary spasm or
ccidental coronary thromboembolism has been proposed
s the causative mechanisms, however without deﬁnite evi-
ence.
Fluffy (frosty glass-like) luminal surface of a non-stenotic
oronary segment was observed in a certain group of
atients with ACS (Fig. 3). The same luminal changes
ere reproduced in animals when blood was perfused after
ndothelial damages. Attachment of ﬁbrin threads and
latelets on the damaged endothelial cells was detected by
istology, suggesting residual thrombus after autolysis. The
amemechanisms may participate in patients with ACS with-
ut signiﬁcant coronary stenosis, or without demonstrable
laque disruption. However, the genesis of endothelial dam-
ge remains to be elucidated [29]. Extensive endothelial cell
poptosis induced through catecholamine--adrenoceptor-
aspase pathway [30] may play a role in this phenomenon.
etection of vulnerable coronary plaques by new
maging modalitieshus, limitation of conventional angioscopy using white light
n detecting vulnerable plaques became evident. Therefore,
he following imaging tools were developed for more objec-
ive diagnosis of vulnerable plaques.
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Figure 3 Fluffy coronary luminal surface. A 51-year-old female with unstable angina (UA). (A) Angiogram of the left coronary
artery. The middle segment of the left anterior descending artery observed by angioscopy is shown by the arrow. The margin of the
segment was irregular (arrow). (B) Angioscopic image of the same segment. The entire circumference of the luminal surface was
. (C)
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Reproduced from Uchida et al. [29] with permission.
Detection of vulnerable coronary plaques by
near-infrared spectroscopy
Discrimination of cholesterol and cholesteryl esters in the
excised human plaques by near-infrared spectroscopy (NIRS)
in vitro was performed by Weinmann and Waxman [31,32].
This method is also applicable for detection of collagens,
low-density lipoprotein, etc. This method has a potential
use for molecular analysis of vulnerable plaques.
Detection of vulnerable coronary plaques by
near-infrared ﬂuorescence angioscopy
Two-dimensional imaging of cholesterol and cholesteryl
esters within human coronary plaques was accomplished by
near-infrared ﬂuorescence angioscopy (NIRFA). The plaques
in human coronary plaques both in vitro and in vivo
were classiﬁed into NIRF absent, homogenous, doughnut-
shaped, and spotty types. Histological examinations showed
that these image patterns were determined mainly by -
carotene-conjugated cholesterol, cholesteryl esters, and
calcium, and the latter two types were considered vulnera-
ble [33] (Fig. 4).
Detection of vulnerable coronary plaques by color
ﬂuorescence angioscopy
Fluorescence of excised human coronary plaques was exam-
ined by color ﬂuorescence angioscopy (CFA) using a 345 nm
band-pass ﬁlter (BPF) and a 420 nm band-absorption ﬁlter
(BAF).
Coronary plaques exhibited blue, green, white-to-light
blue, or yellow-to-orange ﬂuorescence. Fluorescence micro-
scopic studies revealed that collagen subtypes, cholesterol,
cholesteryl esters, calcium, and -carotene determine the
ﬂuorescence color of the plaques. Histological examinations
revealed dense CFs without lipids in blue plaques; dense CFs
and lipids in green plaques; meager CFs and abundant lipids
in white-to-light blue plaques; and the absence of CFs and
deposition of lipids, calcium, and macrophage foam cells in
the thin ﬁbrous cap in yellow-to-orange plaques, indicat-
s
c
g
cThe ﬂuffy surface was diffusely stained blue with Evans blue
ng that the yellow-to-orange plaques were most vulnerable
34] (Figs. 5 and 6).
valuation of progressiveness toward vulnerable
laques
ased upon the knowledge about the pathophysiology of
therosclerosis, in vitro and in vivo and clinical trials have
een performed using different tracers for plaque imaging
tudies, including radioactive-labeled lipoproteins, compo-
ents of the coagulation system, cytokines, mediators of
he metalloproteinase system, cell adhesion receptors, and
ven whole cells [26], or antibodies of the above-mentioned
ubstances.
xidized low-density lipoprotein imaging
xidized low-density lipoprotein (OxLDL) plays a key
ole in the initiation, progression, and destabilization of
therosclerotic plaques [35,36].
Therefore, if oxLDL is visualized in vivo, the fate (pro-
ressiveness) of plaques can be prospected and the effects
n them of medical and interventional therapies can be
ore objectively evaluated.
In the presence of Evans blue dye, oxLDL exhibited violet
nd brown ﬂuorescence by exciting at 345 nm and emitted
t 420 nm (A-imaging) and by exciting at 470 nm and emit-
ing at 515 nm (B-imaging), respectively. This combination
f ﬂuorescence color was not observed in the other major
ubstances composing atherosclerotic plaques. This combi-
ation of ﬂuorescence was observed not only in yellow but
lso in white plaques of excised human coronary artery.
oreover, ﬂuorescence characteristics of oxLDL in the coro-
ary plaques were successfully visualized in patients [34]
Fig. 7).
ysophosphatidylcholine imaging
ysophosphatidylcholine (LPC) is a pro-inﬂammatory sub-
tance, and it is the major bioactive phospholipid
omponent of oxLDL and plays a critical role in the athero-
enic activity of oxLDL [37].
The ﬂuorescence characteristic of LPC in excised human
oronary plaques was investigated by color ﬂuorescence
24 Y. Uchida
Figure 4 Relationships among conventional angioscopic, near-infrared ﬂuorescence angioscopy (NIRFA), and near-infrared ﬂuo-
rescence microscopy (NIRFM) scanned images and histological changes in excised human coronary plaques. From A to D: the images
of coronary plaques by conventional angioscopy. From a to d: corresponding NIRFA images of the same plaques. From  to : cor-
responding NIRFM scanned images of the cut wall surface of the same specimens. From 1 to 4: corresponding histological images
after staining with Oil Red-O and methylene blue. Red and black portions indicate lipids and calcium, respectively. Horizontal bar
at the left upper corner of each panel: 100m. A: a white plaque. From B to D: yellow plaques. a and b: homogenous type. Arrows:
homogenous near-infrared ﬂuorescence (NIRF); c: doughnut-shaped type. Arrow: NIRF absent portion surrounded by strong NIRF
region; d: spotty type. Arrow: spots.  and : homogenous NIRF (arrows); : necrotic core lacking NIRF (arrow) surrounded by strong
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EIRF region; : ﬁbrous cap with strong NIRF spots (arrow). 1: h
eposition in entire plaque; 3: lipid-deposited ﬁbrous cap with
lipid-laden ﬁbrous cap. Red: lipids. Black: calcium compound
eproduced from Uchida et al. [39], with permission
ngioscopy using Trypan blue dye (TB) as an indicator. In
he presence of TB, LPC exhibited a red ﬂuorescence at A-
nd B-imaging. This red ﬂuorescence at A- and B-imaging
as observed in human coronary plaques [38].
holesterol and cholesteryl ester imaging
arg and Waxman succeeded in in vivo imaging of choles-
erol and cholesteryl esters by spectroscopy [32]. The
resent author succeeded in two-dimensional imaging of
holesterol and cholesteryl esters within the coronary
laques using NIRFA in patients [39] (Fig. 8).acrophage imaging
acrophages play an important role in plaque progression.
iscrimination of macrophages and foam cells is difﬁcult
c
r
F
c
penous deposition of lipids deep in the plaque (arrow); 2: lipid
crotic core (NC) below; 4: calcium particles distributed within
ow). Horizontal bar: 100m.
ven by microscopy. Their imaging by angioscopy is still not
uccessful. By imaging cells and molecules, vulnerable
laques can be characterized on a cellular or molecular
asis.
valuation of stabilization and regression of
ulnerable plaques by angioscopy
ipid-lowering therapy
ffects of lipid-lowering therapy using ﬁbrates or statins on
oronary plaques were evaluated by several workers, and
eduction of yellow color grade was observed as shown in
ig. 9 [13,40,41]. However, the changes in yellow plaque
olor induced by these agents were different among the
laques even in a given patient [13].
Recent advances in coronary angioscopy 25
Figure 5 Relationships between images produced by conventional angioscopy, color ﬂuorescence angioscopy (CFA) and color ﬂuo-
rescence microscopy (CFM) scanning. From A to D: conventional angioscopic images of coronary plaques. From a to d: corresponding
CFA images using ‘‘A’’ imaging. From  to : corresponding CFM scanned images using ‘‘A’’ imaging. Horizontal bar: 100m. A:
a white plaque observed during conventional angioscopy (arrow) exhibited blue ﬂuorescence by CFA (arrow in a) and CFM scan
(). B: a yellow plaque observed during conventional angioscopy (arrow) exhibited green ﬂuorescence seen during CFA (arrow in
b) and CFM scan (arrow in ). C: a yellow plaque observed during conventional angioscopy (arrow) exhibited white-to-light blue
ﬂuorescence seen during CFA (c) and deposition of yellow substances in the white-to-light blue area (arrow in). D: a yellow plaque
low ﬂ
) sub
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D
Iobserved during conventional angioscopy (arrow) exhibited yel
(white arrowhead), white (white arrow) and blue (yellow arrow
Reproduced from Uchida et al. [34], with permission.
Molecular or cellular targeting therapy
Targeting therapy of oxLDL, metalloproteinases, or
macrophages may be a promising option for stabilization
and regression of vulnerable plaques. Although invasive,
ﬂuorescence angioscopy may be a promising imaging modal-
ity for direct evaluation of molecular or cellular targeting
therapy of atherosclerotic plaques.
Evaluation of neointimal coverage of coronary
stents by angioscopy
Neointima formation on stent struts is essential for vascu-
lar wound healing process. Drug-eluting stents (DES) inhibit
the mobilization and differentiation of progenitor cells of
endothelial cells and smooth muscle cells, and thus not
only inhibit restenosis but also impair neointima formation,
which may lead to stent thrombosis.
DES have reduced restenosis signiﬁcantly, but their short-
comings became evident, namely insufﬁcient stent strut
coverage by neointima, and consequent late-stent throm-
bosis (LST) or very LST, and consequent ACS which can occur
on termination of anti-thrombotic therapy. This is a typi-
cal example of ‘‘a new therapeutic modality that has a new
complication’’.
a
L
F
Buorescence observed during CFA (d) and deposition of orange
stances in the area of no ﬂuorescence by CFM scanning.
Coronary angioscopy contributed greatly in clarifying
echanisms of neointimal coverage of stent struts and LST
s follows:
rading of neointimal coverage by angioscopy
he thickness of the neointima on the stent struts can be
ssessed by angioscopy based on whether or not the stent
truts can be seen through the neointima.
Higo et al. and Oyabu et al. classiﬁed neointimal coverage
y angioscopy into: grade 0, not covered; grade 1, covered
y a thin layer; and grade 2, buried under neointima [42,43].
ifference in neointimal coverage between bare-metal
nd drug-eluting stents
lthough restenosis rates have been markedly reduced
y DES, it became evident that stent strut coverage by
eointima was incomplete or much delayed in cases of
ES when compared with bare-metal stents (BMS) [43—45].
t was also clariﬁed that neointimal coverage is different
mong DES [46].
ate-stent thrombosis
ig. 10 shows an example of occlusive LST. LST occurs in both
MS and DES. The prevalence was signiﬁcantly higher in the
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Figure 6 Lipids, calcium compounds, collagen ﬁbers (CFs), and macrophage foam cells in the same plaques as those shown in
Fig. 5. From A to D: microscopic images after Oil-red O and methylene blue staining obtained from the same plaques in A to D in
Fig. 5, respectively. Red: lipids. Black: calcium. LC: lipid core. Horizontal bar: 100m. From a to d: CFs stained by silver staining.
No normal CFs in d. Arrow in d: plaque debris. Horizontal bar: 20m. From  to : images of ceramide in macrophage foam
cells obtained by ‘‘B’’ imaging of color ﬂuorescence microscopy (CFM) after Ziel—Neelsen staining. Orange ﬂuorescence (arrows):
macrophage foam cells. Arrowhead in : residual collagen ﬁbers (CFs). Horizontal bar: 20m. A: a plaque without lipids, with
abundant normal CFs (a) and without macrophage foam cells (). B: a plaque with lipids, with thick CFs (b) but without macrophage
foam cells (). C: a plaque with lipid deposition and cavity formation, meager CFs (c) and disseminated macrophage foam cells
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carrow in ). D: a plaque with a thin ﬁbrous cap with lipids and c
oam cells (arrows in ).
eproduced from Uchida et al. [34], with permission.
ES than that in BMS [47], probably due to the higher preva-
ence of neointimal coverage. Awata et al. observed that
ST was more frequently observed in sirolimus-eluting stents
SES) than in paclitaxel-eluting stents (PES) (43% vs 19%) at
months [48]. They also reported that LST was observed in
1% of patients in the SES group versus 6% of patients in the
otalorimus (ZES) group at 6 months.
ossible mechanisms of late-stent thrombosis and
ppropriate neointimal thickening to prevent
estenosis, and neoendothelial cell damages and
onsequent late-stent thrombosis
ndothelial cells are highly anti-thrombotic. The same may
lso be true for neoendothelial cells regenerated after stent
mplantation.
(
1
L
w
nm (arrow in D), without CFs (d) and with multiple macrophage
Neointima acts as a cushion between neoendothe-
ial cells and the stent struts. If the neointima is thin,
tent struts are considered to be dislocated synchroniz-
ng to blood pressure changes and cardiac motion, and
ccordingly induce mechanical stress on the neoendothelial
ells.
The struts were see-through (grade 0—1) by angioscopy
hen the neointima thickness was below 130m by OCT
n patients [49]. LST was observed in grade 0 or 1 group
n patients with DES or BMS [10,26,50]. At 6 months after
tenting, neoendothelial cells were stained in blue with
vans blue dye which selectively stains damaged endothelial
ells when the neointima thickness grade was 0—1 [50,51]
Fig. 11). In animals, the struts were visible (grade 0 or
) when the neointimal thickness was around 88m and
ST was frequently observed when the intimal thickness
as within 100m [51]. All these ﬁndings indicated that
eoendothelial cells were damaged and LST formed on the
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Figure 7 Ox-LDL imaged by color ﬂuorescence angioscopy (CFA) in the coronary artery in a patient with angina pectoris. Reddish
brown ﬂuorescence observed in a non-stenotic proximal segment of the left anterior descending coronary artery after the intra-
coronary injection of EB in a patient with stable angina pectoris. A: an angiogram of the left coronary artery. Arrows a to b: the
proximal segment observed by CFA. The wall of the segment was uneven but signiﬁcant stenosis was not found. From B to E: CFA
images of the same segment obtained after injecting EB, by advancing the angioscope distally from a to b of panel A. Reddish brown
portions indicate ox-LDL. The luminal surface was uneven, indicating early stage of atherosclerosis.
Reproduced from Uchida et al. [34] with permission.
Figure 8 Near-infrared ﬂuorescence angioscopy (NIRFA) study in a 61-year-old male with stable angina. From A to C: angiogram,
conventional angioscopic image and NIRFA image of a plaque in the proximal segment of the left anterior descending coronary artery
(arrow in A). The yellow plaque (arrow in B) presented a homogenous type near-infrared ﬂuorescence (NIRF) image (C). Arrowhead:
guide wire.
Reproduced from Uchida et al. [39], with permission.
Figure 9 Effects of oral administration of bezaﬁbrate on coronary plaques. A: a yellow plaque before administration of bezaﬁbrate
(arrow). B: the yellow plaque (arrow in A) disappeared 6 months later (arrow in B).
Reproduced from Uchida et al. [18] with permission.
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Figure 10 An occlusive stent thrombus (late-stent thrombosis) formed 7 months after bare-metal stent (BMS) deployment. A
and B: A 57-year-old-male in whom ST-elevation myocardial infarction developed 7 months after BMS deployment. Arrow in A:
naked (grade 0) strut. Arrowheads: occlusive red thrombi. Arrow in B: struts and neighboring portions stained blue with Evans blue
indicating neoendothelial cell (NEC) damage and/or ﬁbrin. Arrowheads correspond to those in A.
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rade 1 because the struts were seen through (arrows in A). The
NEC) (arrows in B) damage.
truts when neointimal thickness was within approximately
00m.
Determining exactly how to terminate this ‘‘vicious
ycle’’ is an essential requisite for effective prophylactic
reatment of LST.
Based on the angioscopic results in these clinical and ani-
al studies, the control of neointimal regeneration over
00m and below an appropriate thickness that does not
ause signiﬁcant restenosis is an essential requisite for the
revention of LST and restenosis.
onclusion
ark and glistening yellow coronary plaques observed
y conventional angioscopy using visual light have been
elieved to be vulnerable based on the studies in patients
ith ACS, histological examinations, and on prospective
tudies. Further, the patients having multiple yellow plaques
ave been believed more prone to suffer from ACS. Why
he patients having yellow plaques do not necessarily suf-
er from ACS is a recently raised question. Based on lipids,
ollagen ﬁbers, and calcium distribution patterns, yellow
s
1
e
a
abare-metal stent (BMS) deployment. Neointimal coverage was
ts were stained with Evans blue, indicating neoendothelial cell
oronary plaques are classiﬁed by histology into 7 stable
r vulnerable subgroups and conventional angioscopy can
ot discriminate them. Recently, new imaging modalities
ere developed to discriminate the substances or cells
hat constitute the atherosclerotic plaques, namely near-
nfrared spectroscopy and ﬂuorescence angioscopy and so
n. Employing these imaging modalities, more speciﬁc iden-
iﬁcation of vulnerable plaques can be attained.
DES reduce coronary restenosis signiﬁcantly, however,
ST occurs, which requires long-term antiplatelet therapy.
Angioscopic grading of neointimal coverage of coronary
tent struts has been established, and it was revealed that
eointimal formation is incomplete and prevalence of LST is
igher in DES when compared to BMS. It was also observed
hat the neointima is thicker and LST is less frequent in PES
nd ZES than in SES.
Endothelial cells are highly anti-thrombotic. Clinical and
nimal studies have revealed that neoendothelial cells on
tent struts are damaged when the neointima is less than
00m thick, and LST frequently occurs. In addition to toxic
ffect of drugs or polymers of DES, neoendothelial cell dam-
ge is considered to be caused by friction between the cells
nd stent struts due to the thin neointima between them
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which might act as a cushion. Therefore, it is conceivable
that to control neointimal regeneration over 100m and
below appropriate thickness which does not cause signiﬁcant
restenosis is necessary to prevent LST.
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